(DRTS) Alpha Tau Medical Ltd. Business Model Canvas Research

Alpha Tau Medical Ltd. depends on licensed isotope suppliers and radiation-safety partners because Alpha DaRT uses controlled radioactive materials and strict chain-of-custody handling. These partners keep transport, storage, and site prep compliant, which is critical for running clinical sites without delays.

• Licensed isotope supply
• Secure transport and storage
• Radiation-safety oversight
• Site-readiness support

Alpha Tau Medical Ltd. works with Israeli and U.S. regulators, ethics committees, and public funders because trial approvals and site clearances can shift timelines fast. For a clinical-stage company with no product revenue, non-dilutive grants and public support matter because they can fund studies without adding equity dilution.

• Regulators shape trial start dates.
• Ethics committees gate patient enrollment.
• Public funding can extend runway.

Manufacturing and quality control keep Alpha Tau Medical Ltd.'s clinical supply under tightly controlled conditions, which matters because the product combines radioactive and implantable components. This protects safety, lot-to-lot consistency, and trial reproducibility, all of which are critical in clinical-stage supply chains.

Quality assurance also reduces the risk of dose drift or sterility failures across batches, so each implant used in trials performs the same way. In practice, this means strict release testing, traceability, and controlled handling from production to site delivery.

• Controlled clinical supply
• Radioactive and implantable QA
• Consistency, safety, reproducibility

Alpha Tau Medical Ltd. uses medical evidence generation to prove Alpha DaRT’s clinical value through published data, conference presentations, and key opinion leader input. This work is critical for payer, physician, and investor trust, and it matters more as the company scales from early adoption toward broader clinical use.

• Publishes trial and study data
• Presents at medical conferences
• Engages key opinion leaders
• Validates clinical and economic value

Alpha Tau Medical Ltd.'s scientific and clinical team is a core key resource: people with cancer therapy, trial, and regulatory experience connect R&D, clinical execution, and FDA/EMA work. That expertise shapes trial design, speeds site support, and keeps external messaging credible.

• Drives oncology trial design

• Bridges research and regulation

• Supports investor and KOL communication

Alpha Tau Medical Ltd. is headquartered in Jerusalem, Israel, and that base supports its R and D, clinical operations, and administration. As a clinical-stage company, its capital base is just as important as lab and trial know-how, because funding has to cover ongoing studies, regulatory work, and day-to-day operations before any product sales arrive.

• Jerusalem HQ anchors core functions
• Supports R and D and clinical work
• Cash funding is a key resource
• Clinical-stage model means no sales yet

Alpha Tau Medical Ltd.’s therapy is positioned as a platform, not a one-tumor fix, so the same localized workflow can be repeated across multiple solid-tumor indications. That repeatability supports clinical standardization and a clearer path to broader adoption as the company expands beyond single-site use.

• Platform model across indications
• Repeatable localized workflow
• Supports standardized clinical use

Alpha Tau Medical Ltd.’s short-range alpha emission is designed to limit dose spread, which may reduce collateral damage versus broader radiation. That matters in sensitive sites where even small injury can affect swallowing, speech, or organ function. Ongoing clinical studies are meant to confirm the benefit-risk profile.

• Short-range dose, less off-target exposure
• Fits sensitive anatomical sites
• Clinical validation still key

Alpha Tau Medical Ltd. must train physicians and staff on the therapy workflow and radiation handling, because one unfamiliar step can slow adoption and raise safety risk. In a novel oncology platform, this education also builds trust, cuts operational friction, and supports consistent use across treatment sites.

• Safe handling reduces site-level friction.
• Training supports faster clinical adoption.
• Education builds trust in novel therapy.

Alpha Tau Medical Ltd. keeps customer relationships evidence-led: it builds trust through clinical results, not sales talk. As a pre-commercial biotechnology company in 2025, its communication is mainly driven by study data, publications, and conference presentations, which is standard before broad market launch.

• Clinical outcomes lead the message
• Publications and presentations support trust
• Pre-commercial biotech model

Peer-reviewed publications are a key credibility channel for Alpha Tau Medical Ltd., because they let independent scientists test the clinical data and help build long-term trust in the company’s approach. They also turn trial results into adoption interest by making outcomes easier for physicians, hospitals, and payers to judge.

• Supports scientific scrutiny
• Builds durable trust
• Converts trial data into interest

Alpha Tau Medical Ltd can widen hospital access by using strategic partners in clinical, regulatory, and manufacturing roles, so the company can scale beyond one geography. Its channel setup is most valuable when partners help move from trial sites to multi-country hospital adoption, while keeping regulatory and production support close to each market.

• Broader hospital access
• Clinical and regulatory support
• Manufacturing scale for new markets

Alpha Tau Medical Ltd. targets patients with difficult solid tumors, a group that covers about 90% of adult cancers. Current studies include skin, oral, pancreatic, and breast cancers, while preclinical work broadens the pool beyond today’s trial set; pancreatic cancer still has a 13% 5-year relative survival rate in the U.S.

• Focus: hard-to-treat solid tumors
• Current studies: skin, oral, pancreatic, breast
• Preclinical: expands future patient reach

Health systems and payers are the key post-approval gatekeepers for Alpha Tau Medical Ltd., because they decide reimbursement, site adoption, and rollout speed. They want clear clinical benefit, low workflow friction, and a cost case that beats current options; without that, even strong trial data can stall uptake.

• Reimbursement drives adoption speed.
• Clinical value must be easy to prove.
• Workflow fit affects hospital use.
• Cost justification shapes payer coverage.

Regulatory and compliance costs are a heavy fixed load for Alpha Tau Medical Ltd.: each study needs submissions, audits, legal review, and safety files, while radiation therapy products face oversight in the U.S., EU, and other markets. These costs do not sell the product, but they keep trials alive and can quickly add up when every protocol change needs fresh review.

• Submissions and audits consume staff time.
• Safety documentation is mandatory across markets.
• Compliance spend keeps studies running.

General and administrative overhead is a fixed-cost base for Alpha Tau Medical Ltd., covering headquarters, finance, HR, legal, and corporate governance. As a Jerusalem-based public clinical-stage company, tight admin control matters because this overhead supports a multi-year development pipeline while cash is still being spent on R&D.

• Fixed HQ and governance costs.
• Supports clinical-stage execution.
• Discipline matters for cash use.

If Alpha DaRT wins approval, Alpha Tau Medical Ltd. could earn recurring treatment revenue from hospital use; in FY2025, it still had no commercial product sales, so adoption and reimbursement remain the key drivers of this long-term stream.

• Approval needed first
• Revenue tied to hospital uptake
• Payer reimbursement is critical
• Main long-term operating upside

Alpha Tau Medical Ltd. can license its platform by indication or territory, so it can earn upfront cash and milestone fees before full sales scale. In biotech, partnering deals often pair an upfront payment with development, regulatory, and launch milestones, which can monetize the tech while direct rollout is still limited.

• License by indication or territory
• Collect upfront and milestone cash
• Monetize before full commercialization